AI
WHWK

Atom Investors’s Whitehawk Therapeutics WHWK Stock Holding History

Atom Investors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,333
Closed -$135K – 399
2021
Q2 		$135K Buy
+5,333
New +$122K 0.02% 226

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Atom Investors's WHWK Position: Q3 2021 in Review

Atom Investors sold out of Whitehawk Therapeutics (WHWK) in Q3 2021, closing a stake of 5,333 shares — an estimated $135K sold.

Atom Investors first reported a position in WHWK in Q2 2021 and held it in 1 quarter. The position peaked at $135K in Q2 2021. 33 funds tracked by Wall St. Rank hold WHWK as of Q3 2021.

  • Atom Investors reported no remaining Whitehawk Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Atom Investors sold 5,333 Whitehawk Therapeutics shares in Q3 2021, an estimated $135K.
  • Atom Investors first reported a position in Whitehawk Therapeutics in Q2 2021 and held it in 1 quarter.
  • Atom Investors's Whitehawk Therapeutics position peaked at $135K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2021.

Based on Atom Investors's 13F filing for Q3 2021, filed 15 Nov 2021.